Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 162

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment

Naipal, Kishan A.T., Verkaik, Nicole S., Ameziane, Najim, van Deurzen, Carolien H.M., ter Brugge, Petra, Meijers, Matty, Sieuwerts, Anieta M., Martens, John W., O'Connor, Mark J., Vrieling, Harry, Hoeijmakers, Jan H.J., Jonkers, Jos, Kanaar, Roland, de Winter, Johan P., Vreeswijk, Maaike P., Jager, Agnes, van Gent, Dik C.·2014·Clinical Cancer Research

Abstract

Purpose: Poly(ADP-ribose) polymerase (PARP) inhibitors are promising targeted treatment options for hereditary breast tumors with a homologous recombination (HR) deficiency caused by BRCA1 or BRCA2 mutations. However, the functional consequence of BRCA gene mutations is not always known and tumors can be HR deficient for other reasons than BRCA gene mutations. Therefore, we aimed to develop a functional test to determine HR activity in tumor samples to facilitate selection of patients eligible for PARP inhibitor treatment. Experimental design: We obtained 54 fresh primary breast tumor samples from patients undergoing surgery. We determined their HR capacity by studying the formation of ionizing radiation induced foci (IRIF) of the HR protein RAD51 after ex vivo irradiation of these organotypic breast tumor samples. Tumors showing impaired RAD51 IRIF formation were subjected to genetic and epigenetic analysis. Results: Five of 45 primary breast tumors with sufficient numbers of proliferating tumor cells were RAD51 IRIF formation deficient (11%, 95% CI, 5%–24%). This HR defect was significantly associated with triple-negative breast cancer (OR, 57; 95% CI, 3.9–825; P = 0.003). Two of five HR-deficient tumors were not caused by mutations in the BRCA genes, but by BRCA1 promoter hypermethylation. Conclusion: The functional RAD51 IRIF assay faithfully identifies HR-deficient tumors and has clear advantages over gene sequencing. It is a relatively easy assay that can be performed on biopsy material, making it a powerful tool to select patients with an HR-deficient cancer for PARP inhibitor treatment in the clinic. Clin Cancer Res; 20(18); 4816–26. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-0571

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 162

Metadata

Authors
Naipal, K. A. T., Verkaik, N. S., Ameziane, N., van Deurzen, C. H. M., ter Brugge, P., Meijers, M., Sieuwerts, A. M., Martens, J. W., O'Connor, M. J., Vrieling, H., Hoeijmakers, J. H. J., Jonkers, J., Kanaar, R., de Winter, J. P., Vreeswijk, M. P., Jager, A., & van Gent, D. C.
Venue
Clinical Cancer Research
Published
2014-09-14
Volume
20
Issue
18
Pages
4816-4826
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2161103148
Cited by
162
References
7
FWCI
6.46
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-0571
The paper
Naipal, K. A. T., Verkaik, N. S., Ameziane, N., van Deurzen, C. H. M., ter Brugge, P., Meijers, M., Sieuwerts, A. M., Martens, J. W., O'Connor, M. J., Vrieling, H., Hoeijmakers, J. H. J., Jonkers, J., Kanaar, R., de Winter, J. P., Vreeswijk, M. P., Jager, A., & van Gent, D. C. (2014). Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-0571

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.